SEATTLE, May 08, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS) (“Atossa” or the “Company”), a
clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast
conditions, today announced that it has received notice from NASDAQ that Atossa has regained compliance with NASDAQ minimum closing
bid price listing rule 5550(a)(2). Atossa has received notice from NASDAQ stating, in part, that the "Staff has determined that for
the last 10 consecutive business days, from April 20 to May 3, the closing bid price of the Company's common stock has been at
$1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2) and this matter is now
closed."
About Atossa Genetics
Atossa Genetics Inc. is a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat
breast cancer and other breast conditions. For more information, please visit www.atossagenetics.com.
Forward-Looking Statements
Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and
uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the
risks and uncertainties associated with any variation between preliminary and final clinical results, actions and inactions by the
FDA, the outcome or timing of regulatory approvals needed by Atossa including those needed to commence studies, lower than
anticipated rate of patient enrollment, estimated market size of drugs under development, the safety and efficacy of Atossa's
products and services, performance of clinical research organizations and investigators, obstacles resulting from proprietary
rights held by others with respect to fulvestrant, such as patent rights, potential market sizes for Atossa’s drugs under
development and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including
without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.
Atossa Genetics Company Contact:
Atossa Genetics Inc.
Kyle Guse
CFO and General Counsel
Office: 866 893-4927
kyle.guse@atossagenetics.com
Investor Relations Contact:
Scott Gordon
CoreIR
377 Oak Street
Concourse 2
Garden City, NY 11530
Office: 516 222-2560
scottg@CoreIR.com
Source: Atossa Genetics Inc.
